- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03177993
Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji (FIT)
Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji
Lymphatic Filariasis (LF), scabies and soil transmitted helminths (STH) are common neglected tropical diseases affecting the people of Fiji. There is a dedicated LF eradication program supported by the World Health Organization (WHO), however scabies and STH are currently managed on an individual level with symptomatic treatment as required.
In an attempt to reduce the prevalence of LF globally, research is being undertaken into alternative, more effective treatment options. A recent study in Papua New Guinea demonstrated a new triple drug therapy (ivermectin, diethylcarbamazine and albendazole) is superior to the currently recommended two drug therapy (diethylcarbamazine and albendazole) used by WHO LF programs in the Pacific. However, adverse events were more frequent. Despite no serious adverse events being observed, it is necessary to conduct further studies to review the safety of this new triple therapy before it can be endorsed as an effective mass drug administration (MDA) regimen for LF in endemic countries. Fiji's burden of LF, that has been recalcitrant to previous MDA with diethylcarbamazine and albendazole, make it an ideal site to obtain further efficacy and safety data of the triple therapy.
Ivermectin given to communities as MDA has been proven to be effective in reducing the community prevalence of scabies. What is not known is the effects of one dose versus two doses of ivermectin as MDA. This question will be reviewed within the design of the community randomized study. The prevalence of impetigo in a community is linked to scabies and this will also be reviewed. Ivermectin and albendazole are both effective individually against STH. The effectiveness of this combination of treatment as MDA in Fiji for STH has not been studied. The effectiveness for the individual in the short-term and the community in the longer-term will be reviewed.
In addition, the acceptability and feasibility of the new therapy in communities at risk of these three diseases will be reviewed.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Suva, Fiji
- Ministry of Health and Medical Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All community members that have given written informed consent to participate
Exclusion Criteria:
- No informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IDA 1
Details of dosing:
|
Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream. Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:
In addition if less than 5 years old excluded from ivermectin. Exclusion criteria for permethrin:
Other Names:
|
Experimental: IDA 2
Details of dosing:
|
Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone. Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8. Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:
In addition if less than 5 years old excluded from ivermectin. Exclusion criteria for permethrin:
Other Names:
|
Active Comparator: DA
Details of dosing:
|
Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA). If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA. Exclusion criteria for diethylcarbamazine and albendazole:
Exclusion criteria for permethrin:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency, type, and severity of adverse events reported by participants following treatment with triple drug therapy (IDA) and standard two drug therapy (DA) in LF infected and uninfected individuals in a community as measured by CTCAE v4.03
Time Frame: within 7 days of drug administration
|
Participants will be interviewed and asked to report their general health status at baseline before receiving treatment and daily for the 2 days following treatment (Active Adverse Event Monitoring phase). For 3 to 7 days following treatment, anyone unwell the preceding day will be actively followed, other participants will be interviewed only if they feel unwell and present to the study team (Passive Adverse Event Monitoring phase). At any stage if they describe being unwell, further questions to determine type and severity of symptom(s) experienced will be asked and recorded according to pre-defined adverse event table. If participants report moderate to severe symptoms they will have further medical assessments as required. LF infection status will be determined by Filiarial Test Strip (FTS) and microfilariae (mf) smears. |
within 7 days of drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clearance of microfilariae (mf) and filarial antigenemia following treatment with IDA or DA in LF infected individuals as measured by microfilaria count in 60ul thick blood smears and filarial test strip rapid diagnostic antigen test.
Time Frame: Baseline and 12 months
|
Methods of assessment: FTS and Dried Blood Spot (DBS) for filarial antigenemia, mf smears for microfilariae
|
Baseline and 12 months
|
Prevalence of scabies in study population measured at baseline and 12 months after treatment using the WHO Integrated Management of Childhood Illness (IMCI) skin algorithm
Time Frame: Baseline and 12 months
|
Methods of assessment: Skin examination
|
Baseline and 12 months
|
Prevalence of STH (hookworm, ascaris, trichuris and strongyloides) as measured by Kato-katz or PCR at baseline and 12 months after treatment
Time Frame: Stool collected at baseline (pre-treatment), 4 weeks (individual response), and 12 months (community prevalence).
|
Methods of assessment: Stool samples will be analysed using Kato-katz method, as well as PCR.
|
Stool collected at baseline (pre-treatment), 4 weeks (individual response), and 12 months (community prevalence).
|
Acceptability and feasibility of IDA and DA in communities at risk of LF, scabies and STH as assessed by survey and focus group discussions.
Time Frame: Approximately 4 weeks following treatment
|
Methods of assessment: Acceptability Survey, designed specifically for the Triple therapy studies, Focus group discussions, Interviews with key informants
|
Approximately 4 weeks following treatment
|
Prevalence of impetigo measured at baseline and 12 months after treatment using the WHO Integrated Management of Childhood Illness (IMCI) skin algorithm
Time Frame: Baseline and 12 months
|
Methods of assessment: Skin examination
|
Baseline and 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gary Weil, MD, Washington University School of Medicine
- Principal Investigator: Andrew Steer, PhD, Murdoch Children's Research Institute
- Principal Investigator: Christopher King, MD PHD, Case Western Reserve University
Publications and helpful links
General Publications
- Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, King CL, Weil GJ, Schuster T, Grobler AC, Engelman D, Robinson LJ, Kaldor JM, Steer AC. Community control strategies for scabies: A cluster randomised noninferiority trial. PLoS Med. 2021 Nov 10;18(11):e1003849. doi: 10.1371/journal.pmed.1003849. eCollection 2021 Nov.
- Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, King CL, Weil GJ, Grobler AC, Robinson LJ, Kaldor JM, Steer AC. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial. Clin Infect Dis. 2021 Sep 15;73(6):994-1002. doi: 10.1093/cid/ciab202.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Lymphatic Diseases
- Vector Borne Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Streptococcal Infections
- Gram-Positive Bacterial Infections
- Parasitic Diseases
- Ectoparasitic Infestations
- Skin Diseases, Parasitic
- Skin Diseases, Infectious
- Staphylococcal Infections
- Skin Diseases, Bacterial
- Spirurida Infections
- Secernentea Infections
- Nematode Infections
- Helminthiasis
- Lymphedema
- Mite Infestations
- Staphylococcal Skin Infections
- Filariasis
- Elephantiasis, Filarial
- Elephantiasis
- Scabies
- Impetigo
- Anti-Infective Agents
- Antiparasitic Agents
- Ivermectin
Other Study ID Numbers
- 201607068-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scabies
-
Assistance Publique - Hôpitaux de ParisCompletedIvermectin | Gale | Severe Forms of Scabies | Oral Parasitic DrugFrance
-
Murdoch Childrens Research InstituteBurnet Institute; Lao Tropical and Public Health InstituteNot yet recruitingScabies | Scabies; ItchLao People's Democratic Republic
-
ParaPRO LLCIqvia Pty Ltd; Medpace, Inc.; Concentrics Research; Inotiv Laboratories; BioAgilytixRecruiting
-
Medicines Development for Global HealthCompleted
-
Mylan Inc.Vyne Therapeutics Inc.; DPT Laboratories, Ltd.CompletedScabiesUnited States, Dominican Republic, Honduras, Puerto Rico
-
Mayne Pharma International Pty LtdbioRASI, LLCCompleted
-
Edward Via Virginia College of Osteopathic MedicineCompleted
-
Infectopharm Arzneimittel GmbHWinicker Norimed GmbHNot yet recruiting
-
Medicines Development for Global HealthRecruiting
-
Centre Hospitalier de CayenneRecruiting
Clinical Trials on 3 drug dose - IDA
-
Washington University School of MedicineIndian Council of Medical Research; Case Western Reserve UniversityCompletedDeath to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic FilariasisLymphatic FilariasisHaiti, India, Indonesia, Papua New Guinea
-
Washington University School of MedicineIndonesia University; Case Western Reserve University; Ministere de la Sante... and other collaboratorsCompletedLymphatic FilariasesFiji, Haiti, India, Indonesia, Papua New Guinea
-
Zhejiang UniversityUnknownHyperlipidemias | Hyperglycaemia (Diabetic)China
-
Washington University School of MedicineCase Western Reserve University; University of Health and Allied SciencesCompleted
-
Inmunova S.A.Hospital Italiano de Buenos AiresCompletedHealthy VolunteersArgentina
-
Loyola UniversityNational Cancer Institute (NCI)Active, not recruiting
-
Autoimmune Technologies, LLCCompleted
-
Galapagos NVCompletedCystic FibrosisUnited Kingdom, Australia, Ireland, Germany, Czech Republic
-
Aronora, Inc.Completed
-
Medigene AGWithdrawnAcute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia | Malignant LymphomaNetherlands